Long-term Follow-up - Infliximab Clinical Trials

Placebo Infliximab

Pts.evaluated 192 771

Avg.weeks of follow-up 29.3 36.9

Pts.With 1 or more

serious infections 9(4.7%) 37(4.8%)

Pneumonia 1(0.5%) 9(1.2%)

Cellulitis 0(0.0%) 4(0.5%)

Sepsis 2(1.0%) 4(0.5%)

Skin ulceration 1(0.5%) 1(0.1%)

Infection 1(0.5%) 1(0.1%)

Urinary retention 1(0.5%) 0(0.0%)

Gastroenteritis 1(0.5%) 0(0.0%)

Peripheral gangrene 1(0.5%) 0(0.0%)

Urinary tract infection 2(1.0%) 0(0.0%)

Abcess 1(0.5%) 1(0.1%)

Bursitis 1(0.5%) 0(0.0%)

Gastritis erosive 1(0.5%) 0(0.0%)

Serious Infections

All Studies